Drugs / ASP0598
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04305184 | Sep 2020 → Jan 2023 | chronic otitis media | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASP0598 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04305184 ↗ |
| Route | Other | “ASP0598 Otic solution was administered onto the Tympanic Membrane (TM) through the external auditory canal via syringe.” NCT04305184 ↗ |